Skip to main content

Table 3 PD-L1 expression in SCLC

From: Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

Author

Patientsc

IHC assay

Biopsy types

TC PD-L1 cutoff

Cell type

PD-L1 expression

Antonia et al. [57]

146

28-8/Dako

Archival or fresh

1%

5%

Tumor cell

16.4%

4.8%

Ott et al. [71]

145

22C3/Dako

Archival or fresh

1%

Tumor and

Stromal cell

31.7%

Hyun et al. [72]

92

22C3/Dako

Archival or fresh

1%

Tumor and stromal cell

45.7%

Inamura et al. [77]

74

E1 L3N/CST

Archival

5%

Tumor cell

18.9%

Yasuda et al. [78]

39

22C3/Dako

Archival

1%

Tumor cell

2.5%

Pujol et al. [63]

53

SP142/Ventana

Archival

1%

Tumor and stromal cell

2%

Gadgeel et al. [66]

30

20

22C3/Dako

Archival

1%

Tumor cell

Stromal cell

10%

40%

Schultheis et al. [79].

94d

5H1/Chen’s lab

E1 L3N/CST

Archival

1%

Tumor cell

Stromal cell

0.0%

TIMs, 18.5%

TILs, 48%

Berghoff et al. [41]

32

NA/Dako

Archival

5%

Tumor cell

Stromal cell

34.4%

TIMs, 28.1%

TILs, 25.0%

Yu et al. [80]

194e

SP142/Ventana

28-8/Dako

Archival

1%

Tumor cell

Stromal cell

16.5%

TILs,

56.2%, 44.8%

Kim et al. [81]

120

MAB1561/

R&D system

Archival

1%

Tumor cell

Stromal cell

14.2%

TILs, 23.3%

Komiya et al [82]

99

EPR1161/Abcam

Archival

5%

Tumor cell

82.8%

Ishii et al. [83]

102

NA/Abcam

Archival

5%

Tumor cell

71.6%

  1. Abbreviations: c patients who are PD-L1 evaluable, d small cell carcinomas 94 patients (SCLC 61; extrapulmonary 33), e total 194 patients, LD-SCLC 98,ED-SCLC 96, IHC immunohistochemistry, TC tumor cell, CST cell signaling technology, TIMs tumor infiltration macrophage, TILs tumor-infiltrating lymphocytes, NA not available*